
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is supported by a diversified radiopharmaceutical and precision-diagnostics franchise, led by PYLARIFY, DEFINITY, and Neuraceq, that continues to deliver broad-based revenue and earnings beats, including 1Q26 sales of $377.3 million and gross margin of 67.0%. The positive thesis is reinforced by multiple near-term catalysts, including FDA approval for PYLARIFY TruVu in March, tentative approval for PNT2003, and PDUFA decisions for LNTH-501 and MK6240, while the FDA’s CRL for LNTH-2501 did not raise concerns about safety, efficacy, or the company’s submitted data. With 2026 guidance reiterated conservatively and a path toward 2027 re-acceleration through stronger reimbursement, improved manufacturing efficiency, and potential royalty contributions from Flyrcado and Pylclari, the stock appears de-risked and positioned for margin and growth expansion.
Bears say
Lantheus Holdings is viewed negatively because its business is highly concentrated in PYLARIFY and DEFINITY, which represented over 80% of total sales in 2022, leaving the company vulnerable to any disruption in either platform. Pricing pressure from more aggressive competitors, slower-than-expected PYL stabilization into 1H26, and uncertainty around “PYL 2.0” approval or TPT status beyond Oct. 2026 all threaten the company’s growth trajectory and commercial footprint. The outlook is further weakened by execution risk tied to the LMI/Evergreen integrations, leadership transitions, and dependence on third-party payors and Medicare, while any break in its just-in-time radiopharmaceutical supply chain could quickly disrupt operations.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Lantheus Holdings (LNTH) Forecast
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares